We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Eli Lilly (LLY) USD (CDI)

Sell:$725.94 Buy:$725.95 Change: $19.64 (2.63%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Change: $19.64 (2.63%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Change: $19.64 (2.63%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Contact details

Lilly Corporate Ctr
Drop Code 1094, Lilly Corporate Ctr
United States
+1 (317) 2762000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$713.81 billion
Shares in issue:
950.77 million
New York Stock Exchange
United States
US dollar

Key personnel

  • David Ricks
    Chairman of the Board, President, Chief Executive Officer
  • Anat Ashkenazi
    Chief Financial Officer, Executive Vice President
  • Diogo Rau
    Executive Vice President, Chief Information and Digital Officer
  • Daniel Skovronsky
    Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
  • Alonzo Weems
    Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
  • Anat Hakim
    Executive Vice President, General Counsel, Secretary
  • Eric Dozier
    Executive Vice President - Human Resources and Diversity
  • Edgardo Hernandez
    Executive Vice President, President - Manufacturing Operations
  • Patrik Jonsson
    Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA
  • Johna Norton
    Executive Vice President - Global Quality

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.